← Back to Home

DRC launches Bundibugyo virus vaccine trial, first testing whether Ervebo can provide cross-virus protection

With no vaccine yet approved against Bundibugyo virus, the Tumaini trial has begun vaccinations and is preparing to include new candidates designed specifically for the virus. Key questions are whether an existing Ebola vaccine’s protection can extend to this virus and how to build reliable evidence for high-risk groups during an outbreak.

By SURL BioNews

Both viruses cause Ebola virus disease, but vaccine protection against them cannot simply be assumed to be equivalent. The Democratic Republic of the Congo is facing an outbreak of Bundibugyo virus (BDBV), for which no vaccine is currently approved. The Tumaini Phase 2/3 trial in Bunia, Ituri province, has vaccinated its first participant, aiming to identify tools that can safely and effectively protect people at high risk during the outbreak response.

Announcements still differ on the exact date of the first vaccination: Médecins Sans Frontières USA said on October 26 that the first participant was vaccinated that day, while announcements from the Coalition for Epidemic Preparedness Innovations (CEPI) and the Institute of Tropical Medicine Antwerp (ITM) both give October 23 as the date. This discrepancy remains to be clarified, but all parties confirm that vaccinations have begun in Bunia.

Ervebo is the first vaccine to enter the trial. It is approved to prevent disease caused by Zaire ebolavirus, but its existing approval does not cover Bundibugyo virus. Its use here is therefore intended to test whether it provides protection against another virus; the launch of the trial itself cannot yet be taken as evidence of effectiveness.

Tumaini is jointly led and sponsored by the Democratic Republic of the Congo’s National Institute of Biomedical Research and the University of Antwerp. It uses an adjustable “adaptive platform” design that allows multiple vaccine candidates to be evaluated within the same research framework. Vaccination follows a ring strategy, focusing on people at higher risk of infection, such as contacts of cases, and embedding the research in the outbreak response.

In addition to Ervebo, two vaccine candidates specifically targeting Bundibugyo virus—one developed by Moderna and the other jointly developed by the University of Oxford and the Serum Institute of India—are preparing to join. Vaccine candidates must undergo independent prioritization by a World Health Organization expert group, and the relevant trial protocol amendments require approval from Congolese regulators. Tumaini is distinct from another study, BRAVO, which specifically evaluates Ervebo’s efficacy against Bundibugyo virus.

The study also includes pregnant women and children aged 12 and older; children as young as one year old can be included for Ervebo. This offers an opportunity to obtain more direct evidence for groups often underrepresented in clinical research. However, inclusion in the study does not mean that safety and protection have already been established; both still require follow-up assessment.

ITM is responsible for laboratory work and immunogenicity assessments, examining which immune responses the vaccines elicit and whether those responses are associated with protection. If a reliable association can be established, vaccine candidates introduced later, or even those that become available for research only after the outbreak, could have a better-supported benchmark for comparison. However, an immune response still cannot be directly equated with proven prevention of disease.

Manufacturing and deployment remain steps between obtaining research results and making vaccines available. CEPI said that Gavi, the Vaccine Alliance, has committed up to US$40 million to support manufacturing readiness so that supply can be expanded once vaccines are authorized for deployment. The most important development for now is that vaccine evaluation has reached the vaccination stage; which vaccine can provide how much protection, and how long that protection lasts, remain questions for subsequent data.

References

  1. Médecins Sans Frontières
  2. Coalition for Epidemic Preparedness Innovations (CEPI)
  3. Institute of Tropical Medicine Antwerp